Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Johnson and Johnson
McKesson
Harvard Business School
Medtronic

Last Updated: November 26, 2022

CLINICAL TRIALS PROFILE FOR TRIAZOLAM


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Triazolam

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00671632 ↗ Behavioral and Subjective Efficacy of Ramelteon in Subjects With a History of Polydrug Abuse Completed Takeda Phase 2 2003-06-01 The purpose of this study is to determine the relative abuse potential of ramelteon, once daily (QD), compared to triazolam in subjects with a history of drug abuse.
NCT00695630 ↗ Flumazenil Reversal of Oral Triazolam Completed National Institutes of Health (NIH) Phase 1/Phase 2 2006-09-01 An increase in the utilization of anesthesia and sedation medications by non-anesthesiologists, including dentists, has grown dramatically. This has been prompted, in part, by the need for pharmacological tools to address high levels of fear and anxiety about dental care among the US population and the evidence of oral health disparities among those who are fearful . Given the prevalence of dental fear in the general population and in the various populations with the greatest burden of oral diseases, effective sedation techniques are needed that are safe and effective in the hands of general dentists that make up the "front line" in the efforts to reduce oral health disparities. This study is to determine whether, when compared to a saline placebo, a single intraoral submucosal administration of the benzodiazepine antagonist flumazenil (0.2 mg) is capable of attenuating in 10 minutes or less the central nervous system (CNS) depression produced by a paradigm of stacked sublingual dosing of triazolam (3 doses of 0.25 mg over 90 minutes).
NCT00695630 ↗ Flumazenil Reversal of Oral Triazolam Completed University of Washington Phase 1/Phase 2 2006-09-01 An increase in the utilization of anesthesia and sedation medications by non-anesthesiologists, including dentists, has grown dramatically. This has been prompted, in part, by the need for pharmacological tools to address high levels of fear and anxiety about dental care among the US population and the evidence of oral health disparities among those who are fearful . Given the prevalence of dental fear in the general population and in the various populations with the greatest burden of oral diseases, effective sedation techniques are needed that are safe and effective in the hands of general dentists that make up the "front line" in the efforts to reduce oral health disparities. This study is to determine whether, when compared to a saline placebo, a single intraoral submucosal administration of the benzodiazepine antagonist flumazenil (0.2 mg) is capable of attenuating in 10 minutes or less the central nervous system (CNS) depression produced by a paradigm of stacked sublingual dosing of triazolam (3 doses of 0.25 mg over 90 minutes).
NCT00894699 ↗ A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTabâ„¢ in Patients Undergoing an Elective Abdominal Liposuction Procedure Completed AcelRx Pharmaceuticals, Inc. Phase 2 2009-06-01 The purpose of this study is to evaluate the safety and effectiveness of a study medication that contains a combination of a pain medication, sufentanil, and a sedative, triazolam. This drug is being designed to provide mild sedation as well as reduce anxiety and pain before and during a procedure (in this case elective abdominal liposuction).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Triazolam

Condition Name

Condition Name for Triazolam
Intervention Trials
Healthy 4
Anxiety 2
Sedation 2
Dental Anxiety 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Triazolam
Intervention Trials
Neoplasms, Plasma Cell 1
Vitreous Hemorrhage 1
Somatoform Disorders 1
Dissociative Disorders 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Triazolam

Trials by Country

Trials by Country for Triazolam
Location Trials
United States 9
Belgium 2
Germany 1
Switzerland 1
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Triazolam
Location Trials
Pennsylvania 1
Massachusetts 1
Texas 1
Georgia 1
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Triazolam

Clinical Trial Phase

Clinical Trial Phase for Triazolam
Clinical Trial Phase Trials
Phase 4 5
Phase 3 3
Phase 2 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Triazolam
Clinical Trial Phase Trials
Completed 13
Not yet recruiting 3
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Triazolam

Sponsor Name

Sponsor Name for Triazolam
Sponsor Trials
Pfizer 3
Holbaek Sygehus 1
American Academy of Sleep Medicine 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Triazolam
Sponsor Trials
Other 25
Industry 8
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Moodys
Medtronic
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.